The cell surface glycoprotein MUC1 is a particularly appealing target for antibody targeting, being selectively overexpressed in many types of cancers and a high proportion of cancer stem-like cells. However the occurrence of MUC1 cleavage, which leads to the release of the extracellular alpha-subunit into the circulation where it can sequester many anti-MUC1 antibodies, renders the target to some degree problematic. To address this issue, we generated a set of unique MUC1 monoclonal antibodies that target a region termed the SEA domain that remains tethered to the cell surface after MUC1 cleavage. In breast cancer cell populations, these antibodies bound the cancer cells with high picomolar-affinity. Starting with a partially humanized antibody, DMB5F3, we created a recombinant chimeric antibody that bound a panel of MUC1+ cancer cells with higher affinities relative to cetuximab® (anti-EGFR1) or tratuzumab® (anti-erbB2) control antibodies. DMB5F3 internalization from the cell surface occurred in an efficient temperaturedependent manner. Linkage to toxin rendered these DMB5F3 antibodies to be cytotoxic against MUC1+ cancer cells at low picomolar concentrations. Our findings show that high affinity antibodies to cell-bound MUC1 SEA domain exert specific cytotoxicity against cancer cells, and they point to the SEA domain as a potential immunogen to generate MUC1 vaccines.
Introduction
MUC1 is a mucin-like glycoprotein which can generate a variety of differing isoforms (1) . Of these, the most intensely studied has been a polymorphic type I high molecular weight transmembrane protein (MUC-TM) consisting of an extracellular domain containing tandem repeats of 20 amino acids, followed by a transmembrane domain and a short cytoplasmic tail (2) (3) (4) . MUC1 is a heterodimer which is cleaved soon after synthesis within the SEA module, a highly-conserved domain of 120 amino acids (4) (5) (6) . Cleavage of MUC1 yields two unequal chains: a large extracellular alpha subunit containing the tandem repeat array specifically bound in a strong non-covalent interaction to a smaller beta subunit containing the transmembrane and cytoplasmic domains of the molecule(4, 7).
MUC1 is highly expressed on a range of malignancies, including breast, pancreas, ovarian, prostate, and colon carcinomas, as well as on the malignant plasma cell of myeloma (8) (9) (10) (11) (12) (13) .
Because of this overexpression, MUC1 has been the subject of a great amount of attention, primarily for its potential as a target for tumor-specific therapies. In fact, based on a number of ranked criteria required of an optimal cancer vaccine candidate, the MUC1 protein was listed by the National Cancer Institute Pilot Project the second best target from a list of 75 potential tumor associated antigens (14) . Moreover, within the categories of expression level, stem cell expression and number of patients with antigen-positive cancers, the MUC1 protein received perfect scores (14) .
Most anti-MUC1 antibodies reported to date target the highly-immunogenic tandem repeat array of the MUC1 alpha chain, [for example (15) (16) (17) ]. Since the MUC1 alpha chain is not directly tethered to the cell surface, it is also found in the peripheral circulation. There it sequesters circulating anti-tandem repeat antibodies, limiting their ability to reach the MUC1+ tumor cells (15, 16) . In addition, deposition of immune complexes of anti-tandem alpha chain antibodies and circulating alpha chain potentially may result in end-organ damage (16) .
Targeting MUC1 epitopes bound to the cell surface would avoid antibody sequestration by circulating alpha chain. The MUC1 SEA domain formed by the interaction of the alpha-subunit with the extracellular portion of beta-subunit is an intricate structure which remains fixed to the cell surface (4, 6) and significantly, results in a stable target structure. In previous initial studies we demonstrated the proof-of-principle of generating antibodies that specifically recognize the MUC1 SEA domain (18) . The prototype DMC209 mAb described (18) has two disadvantages that compromise its potential clinical use: It is an IgM and it has relatively low affinity for its target.
As a result of these considerations, we sought highly specific, anti-MUC1 antibodies directed against the alpha/beta junction, that were also affinity-maturated and not of the IgM subclass.
We report here the generation of seven novel monoclonal antibodies, five Ig-gamma1 and two
IgA, that bind the MUC1 protein within its SEA domain with picomolar affinities. Our findings suggest that the IgG1 and IgA mAbs targeting the MUC1 SEA domain may prove beneficial in the therapy of MUC1+ malignancies when either administered alone or in conjunction with other anti-tumor antibodies and chemo-cytotoxic agents.
MATERIALS AND METHODS

Materials and antibodies
Reagents and chemicals were obtained from Sigma (St. Louis, MO), unless otherwise specified. Anti-MUC1 SEA-module monoclonal antibodies were generated as described below. The anti-MUC1 tandem-repeat antibodies used here were as previously described (19, 20) .
Cell lines Human breast carcinoma lines T47D, MCF7 and ZR-75, human epidermoid carcinoma A431 and KB cell lines, human gastric carcinoma N87 cell line and human pancreatic carcinoma Colo357 cell line were maintained as previously described (18) .
Cell Culture Cells were grown at 37 0 C and 5% CO 2 , in culture media supplemented with 10% heatinactivated fetal calf serum, 2mM L-glutamine, 100 IU/ml penicillin and 25mg/ml streptomycin.
DA3 (mouse mammary tumor cells) and CHO-KI (Chinese Hamster Ovary cells) were grown in
Dulbecco's modified Eagle's medium (DMEM) or DMEM: F12 nutrient mixture(1:1), respectively.
Generation of stable DA3 mouse mammary tumor cell transfectants expressing MUC1-TM DA3
cells were co-transfected with the eukaryotic expression plasmids pCL-MUC1-TM and with pSV2neo (which codes for neomycin resistance). Expression constructs were transfected into cells using the calcium phosphate procedure. Stable transfectants were selected with neomycin. together with incomplete Freund's adjuvant was then used to boost the mice. Bacterially synthesized recombinant MUC1-Xex protein used for these immunizations, spontaneously selfcleaves as previously described (4), generating the MUC1-X alpha and beta subunits that strongly, yet non-covalently, interact with each other forming the very stable heterodimeric cleaved MUC1-Xex protein (depicted in Figs. 1 and 4 ). Hybridomas were prepared by fusion of nonsecreting myeloma cells with immune splenocytes and screened by ELISA assay (see below).
Immunization of mice and generation of hybridomas
ELISA for determining binding of anti-MUC1 polyclonal and monoclonal antibodies to the extracellular domain of the MUC1-X protein
ElisaImmunoAssay plates (Costar, Corning, NY) were coated with recombinant MUC1 proteins followed by blocking. Spent culture media from the initial hybridomas was then applied to the wells. Following incubation, samples were removed and the wells were washed with PBS/Tween. Detection of bound antibodies was performed with HRP-conjugated anti-mouse antibody.
Two-tiered screening for selection of anti-MUC1 monoclonal antibodies
The primary screen of the hybridomas was performed by assessing antibody binding to the extracellular domain of MUC1-X (MUC1-Xex) as described in the ELISA assay (above). To select hybridomas secreting antibody that recognize not only MUC1-Xex but also the complete cell surface MUC1-TM protein, those hybridomas presenting a positive signal in the first screen were subjected to a second-tier screen.
This consisted of flow cytometric analysis using mouse cell transfectants (DA3-TM) expressing human MUC1-TM and, in parallel, to the same parental cells (DA3-PAR) that do not express human MUC1. This procedure ensured selection of antibody that not only bound MUC1 moieties common to both the MUC1-X and MUC1-TM, but also recognized cell surface human MUC1-TM as expressed by mammalian cells. subpopulation that has been reported to show some characteristics of cancer stem cells (22) were isolated as described by Finn (22) . Briefly, MCF7 cells were stained with the fluorescent dye Hoechst 33342. Due to their increased efflux of the dye a side population (SP) of MCF7 cells was isolated by flow cytometry. The resultant cells were then confirmed as showing some characteristics of stem cells using a battery of stem cell markers.
Isolation of MCF7 breast cancer side population of cancer cells
Preparation of ZZ-Pseudomonas exotoxin and chDMB5F3:ZZ-PE38 immunotoxin The ZZ-PE38
fusion protein is comprised of the Pseudomonas exotoxin PE38 and the ZZ-domain derived from Protein A. The ZZ portion binds to the Fc region of IgG to form immunotoxin conjugates. Plasmid pET22-NN-ZZ-PE38 was used for expression of soluble ZZ-Pseudomonas exotoxin A (PE38) fusion protein secreted to the periplasm of BL-21 (DE3) Escherichia coli cells which was then purified as previously described (23) .
SDS-Polyacrylamide protein gel electrophoresis (SDS-PAGE)
Proteins separated on SDS PAGE were electro-transferred for 2 hours at 0.5Amp on to nitrocellulose filters in transfer buffer. Blots were blocked with 5% skimmed milk followed by incubation with the primary antibody (anti-MUC1
antibodies, see Results). Bound primary antibody was detected with secondary anti-mouse antibody conjugated to horseradish peroxidase (Chemicon International, Temecula, CA) followed by enhanced chemiluminescence. 
Cell killing assay
Results
Generation of monoclonal antibodies to the cell-bound MUC1 alpha/beta junction To avoid generating antibodies to the circulating α chain, the MUC1 immunogen should ideally be cellbound at all times. To comply with these criteria we used the extracellular domain of the naturally occurring MUC1-X isoform that incorporates elements derived from both the extracellular alpha chain and the cell bound beta chain. This provided the advantage of incorporating the cell bound region consisting of the alpha/beta junction present in the full naturally occurring MUC1 protein (Fig. 1 ), yet at the same time is devoid of the highly immunogenic tandem-repeat array (Fig. 1, MUC1 -X). The MUC1 protein used for these immunizations is cleaved MUC1-Xex protein synthesized in bacteria. Within the bacteria, MUC1-Xex undergoes spontaneous self-cleavage, and comprises the non-covalently interacting MUC1 alpha and beta subunits.
Using our immunization protocol (Methods), high titer anti-MUC1-X polyclonal antibody sera up to 1:100,000 dilutions were obtained. Spleens of such mice were used for hybridoma formation and hybridoma supernatants subjected to a two-tiered screen consisting of (a) binding to MUC1-X protein, and (b) a more stringent second tier assessing binding to MUC1-expressing cancer cells as assayed by flow cytometry. Hybridoma formation resulted in seven monoclonal antibodies, five of the Ig-gamma1 isotype, designated DMB-4B4, DMB-4F4 , DMB-5F3, DMB7F3 and DMB10F10 . Surprisingly two monoclonals of the IgA subclass were also isolated, DMB10B7 and DMB13D11.
Cytometric analyses of monoclonal anti-junctional antibodies Flow cytometric analyses
demonstrated that all seven monoclonal antibodies bound strongly to DA3-TM cells that express the full length MUC1. In contrast, untransfected DA3-PAR cells which do not express MUC1 were consistently negative with all antibodies (Fig. 2) . Similarly, Colo357, a MUC1+ pancreatic cancer cell line showed unequivocal reactivity with all anti-MUC1 monocolonals ( Despite our characterization of the SP as described above, the MCF7 SP is itself a nonhomogeneous population of cells (22) The DMB mAbs all recognize the SEA domain yet are different from one another The DMB mAbs were assessed by ELISA for binding to the MUC1-Xex protein, the SEA domain itself and the SEA-4G protein, a mutant construct consisting of uncleaved α−β bound by a 4 glycine peptide (6).
These proteins were generated in bacteria, and as previously reported (4), the MUC1-Xex and SEA domain proteins spontaneously self-cleave in bacteria, at the cleavage site FRPG|SVVV, where | indicates cleavage, generating the interacting alpha and beta subunits (depicted in Figure 4 , bottom schema). The mutant SEA-4G protein (depicted in Figure 4 , bottom schema) comprises the amino acid sequence FRPGGGGSVVV (instead of the above wild type sequence), resulting in a non-cleaved protein as previously described (6) . Results showed that all seven mAbs bound the three proteins (each bound to wells of an ELISA plate) at picomolar antibody concentrations and confirmed that the primary target of these antibodies is the SEA domain. The epitopes of anti-SEA module monoclonal antibodies DMB5F3, DMB4F4, and DMB4B4 are largely conformational and involve elements contributed by both the alpha and the beta subunits To define the nature of the epitopes bound by the anti-SEA antibodies, they were assessed by western blotting with a series of SEA module constructs. Staining of SDS-PAGE gels of the SEA module (Fig. 4, bottom panel, A) shows its cleaved constituent alpha and beta chains, as well as protein SEA-4G, a mutant construct consisting of uncleaved alpha-beta bound by a 4 glycine peptide (6) . As expected, probing western blots with the previously described anti-beta subunit specific mAb BOS10D2 (26) (linear epitope indicated in bottom schema, Fig. 4) demonstrates reactivity with the beta subunit but none at the position of the alpha-subunit (lane 1). It further demonstrates strong binding to the alpha-4G-beta construct (lane 2) as well as to small amounts of uncleaved alpha/beta protein (4)( lane 1). Antibodies DMB5F3 and DMB4F4 in contrast react strongly with uncleaved alpha-4G-beta but are non-reactive with both the alpha and beta subunits (Fig. 5 , Panels C and D, respectively). Removal of SDS during the blotting procedure likely allows uncleaved alpha-4G-beta protein to adopt a structure similar to that of the SEA module, previously shown to form an unusually stable three-dimensional structure (6) . In contrast, Panel E demonstrates that antibody DMB4B4 reacts with none of the proteins, not with alpha, not with beta subunits in isolation, nor with the alpha-4G-beta mutant isoforms, suggesting that its binding site requires the presence of both the alpha and beta chains in an epitope resulting from conformationally-determined cleavage.
Affinity of anti-junctional antibodies
Having demonstrated the specificity of the DMB monocolonals to a MUC1 cell-bound domain, the antibodies were examined by serial dilutions to evaluate their affinity for intact in situ cell surface MUC1. To do so, the antibodies were reacted with ZR-75 MUC1+ breast cancer cells in flow cytometry (Methods). ZR-75 was reacted with the antibodies at an initial concentration of 4 microgram/ml. As seen in Figure 5 (upper panel, left), all three antibodies, DMB-4B4, DMB-4F4, and DMB5F3 showed binding at that concentration. At 1 microgram/ml binding of DMB-4B4 and DMB-4F4 was diminished, whereas DMB5F3 clearly showed binding (Fig. 5, middle panel) . DMB5F3 continued to bind the ZR-75 cells to a concentration as low as 62ng/ml (Fig. 5, right panel) .
Binding affinity of DMB5F3 by Surface Plasmon Resonance (SPR)
As DMB5F3 showed the highest binding affinity, we concentrated further studies on this
antibody. An SPR binding assay was performed with serial dilutions of DMB5F3 ranging from 7nM to 0.4nM as described in Methods. Over a period of 2250 seconds, the degree of dissociation is almost imperceptible in each of the seven curves shown (Fig. 5) . These studies were extended to In order to demonstrate that chimeric DMB5F3 generated by mammalian cells retains its specific anti-MUC1 activity, recombinant chDMB5F3 was produced in CHO cells. To assess chDMB5F3
immunoreactivity, wells were coated with MUC1-Xex protein and reacted with dilutions of either recombinant chDMB5F3 or mouse hybridoma DMB5F3 mAb (Fig. 6 , panels C and D, respectively).
Both antibodies bind the MUC1-Xex protein at similar low picomolar concentrations (Fig. 6 , panel D). Flow cytometry analyses confirmed both the specificity and remarkably strong affinity seen with DA3 cells transfected with human MUC1 (Fig. 6G and H) , human adenocarcinoma cells showed that following incubation at 4 0 C labeled DMB5F3 was limited to the cell membrane, indicating binding only to the cell surface (Fig. 7A) . Subsequent incubation at 37 o C demonstrated almost complete relocalization of the labeled antibody to within the cell, reflecting highly efficient internalization into the cell interior (Fig. 7A') . Having demonstrated internalization of chDMB5F3 to MUC1-positive human adenocarcinoma cells, we next proceeded to assess the cytotoxicity of immunotoxin formed with chDMB5F3, and to compare its activity with that of Erbitux and Herceptin immunotoxins. Fixed cells demonstrated similar cell-membrane reactivity with both chDMB5F3 and Erbitux (Fig. 7, B and B', respectively) , and to Herceptin (data not shown). Recombinant chDMB5F3:ZZ-PE38 reacted with the MUC1+ human pancreatic cancer cell line Colo357 resulted in cell killing, and serial dilutions of the antibody revealed an IC50 of approximately 16pM (Fig. 7C ). However when chDMB5F3:ZZ-PE38 was reacted with Colo357 simultaneously with soluble recombinant extracellular domain of MUC1-X (MUC1-Xex), competition was seen with a resultant marked reduction in cell killing (Fig.7C, orange dotted   curve) . In order to demonstrate the specificity of that competition, soluble MUC1 Xex was added to Erbitux:ZZ-PE38 at an equal concentration. MUC1 Xex failed to abrogate Erbitux immunotoxin activity (Fig. 7C, blue dotted curve ) . In a similar way, serial dilutions of chDMB5F3:ZZ-PE38 reacted with ZR75 breast cancer cells showed highly effective killing with an IC50 of 3pM whereas addition of MUC1 Xex competitor abolished cell killing (Fig. 7D , compare continuous and dotted orange lines). While reaction of Herceptin:ZZ-PE38 to ZR75 cells resulted in cell killing, addition of MUC1 Xex did nothing to abrogate cell death (Fig. 7D , compare continuous and dotted green lines). Cell lines such as A431 (epidermoid carcinoma) and N87 (gastric carcinoma) that were found to be only very slightly positive for MUC1, as assessed by flow cytometry with DMB5F3 mAbs, were not affected by the chDMB5F3:ZZ-PE38 immunoconjugate (data not shown).
Taken together these results demonstrate the specificity of cell killing mediated by the chDMB5F3:ZZ-PE38 immunotoxin, and furthermore demonstrate that in certain cancer lines, anti-MUC1-SEA module DMB5F3 immunotoxin is the most potent of the toxin conjugates tested. 
Discussion
Despite its potential to serve as an effective immunotherapeutic agent for a variety of highexpressing MUC1 malignancies, the MUC1 molecule has proved to be an elusive prey. This is in large measure due to the failure to identify and target MUC1 moieties that are permanently cell bound (27) .
Almost all anti-MUC1 antibodies reported to date are directed against the highly immunogenic polymorphic array of 20-125 tandem repeats of a 20 amino acid sequence present in the MUC1 alpha chain [for example, (17) (28-30)]. As the alpha chain is bound non-covalently with the cellbound beta subunit, it is often shed from the surface of MUC1+ cells and freely circulates peripherally. It is here that the shed alpha-subunits sequester anti-tandem repeat array antibodies thereby precluding their ability to reach MUC1+ tumor cells (15, 16) .
We previously described mechanisms whereby the cleaved junction composed of the MUC1 alpha and beta chains is formed (4). Specifically, we analyzed the potential for cleavage of an MUC1-X isoform that contains the same intra-cellular and membrane domains as the full MUC1-TM molecule (4) . While the extracellular domain of MUC1-TM contains the highly immunogenic tandem repeat array, the extracellular domain of MUC1-X is comprised solely of the 120 amino acid SEA module fused to a 30 N-terminal amino acid segment of MUC1, resulting in a less complex structure. Significantly, not only is the MUC1-X alpha/beta junctional isoform cleaved, it is cleaved at an identical site as is the full-length MUC1-TM molecule and therefore results in the same noncovalent interaction of the alpha and beta subunits(4).
All seven anti-MUC1 monoclonal antibodies described here are directed against the cell-bound MUC1 SEA domain that embraces the MUC1 alpha/beta junction. Since the membrane-bound alpha/beta junction involves an intricate structure of alpha helices and intertwined beta strands (6) , antibodies directed against the native structure would likely recognize epitopes composed of elements contributed by both the alpha-and beta-subunits. As shown (Fig. 4) (Fig. 6) . This is consistent with the previously reported cytocidal activity of PE38-immunconjugates against pancreatic cancer cells and against hairy cell leukemia (33, 34). In addition, the cytotoxic activity of chDMB5F3 immunoconjugate was compared to that of PE38 immunotoxins formed with Cetuximab (Erbitux ®) (anti-EGFR) (35) and with Trastuzumab (Herceptin®, anti-ErbB2 or Her2) (36) . In human cancer cell lines assessed for their sensitivity to the three immunotoxin conjugates, chDMB5F3:ZZ-PE38 resulted in cytotoxicity comparable or superior to the Cetuximab and Trastuzumab conjugates in pancreatic and breast cancer cells (Fig.   7) .
To assess the anti-tumor activity of the chDMB5F3:ZZ-PE38 immunoconjugate within the intact organism, we have recently initiated a study that utilizes a nude mouse model of pancreatic tumor growth using MUC1-positive human pancreatic cancer cells. To date, our in-vivo findings show abrogation of tumor growth corroborating the potent in-vitro cytocidal activity of chDMB5F3:ZZ-PE38 (to be presented in a separate publication). (42) , including ADCC (antibody dependent cell mediated cytotoxicity) and CDC (complement dependent cytotoxicity). We do not know as yet whether this will be the case for all or any of the DMB mAbs reported here. Antibodies against the tandem repeat part of MUC1 fail to induce complement lysis despite appreciable binding by flow cytometry. This has been attributed to the great distance from the cell surface that complement is activated (43) . In this regard it is pertinent to note that all DMB mAbs bind MUC1-SEA-domain epitopes that are located close by to the cell membrane making CDC a distinct possibility for DMB mAbs. indicated by alpa and beta) or the alpha and beta subunits connected by the four-glycine residue linker (alpha-4G-beta). Identical gels were western blotted and probed with monoclonal antibodies BOS10D2, DMB5F3, DMB4F4 or DMB4B4 (panels B-E, respectively). The epitope recognized by the BOS10D2 antibodies has been previously reported (26) and is indicated in the lower panel. Color scheme of the protein segments is the same as in Fig. 1 . (Panel G) on DA3-PAR, DA3-TM and human breast cancer T47D cells by applying varying levels of chDMB5F3 antibody, as indicated on the x-axis, together with ZZ-PE38. Cell viability (y-ordinate) was assessed using the alkaline phosphatase assay (Methods). 
